Schering-Plough Receives FTC Clearance for Organon Acquisition

Schering-Plough has received antitrust clearance from the FTC regarding its planned acquisition of Dutch drugmaker Organon BioSciences from Akzo Nobel.

Organon BioSciences is comprised of Organon, a human pharmaceutical business, and Intervet, an animal health business. It also includes Nobilon, a human vaccine development unit, and Diosynth, a third-party manufacturing unit.

Schering-Plough and Intervet will divest three poultry vaccines in the U.S. No divestiture of human health products is required.

Schering-Plough received approval from the European Commission Oct. 11 and said it expects the transaction to be completed by the end of the year.